Assessment by a two-site enzyme immunoassay of human epidermal growth factor (urogastrone) in the urine of patients with various gastrointestinal diseases including malignant tumors.
By using our two-site enzyme immunoassay (EIA) system, the levels of human epidermal growth factor (hEGF) in the urine of patients with various gastrointestinal diseases including malignant tumors were measured. Urinary excretion of hEGF in patients having undergone gastric resection, expressed as a function of creatinine, was found to be somewhat decreased. While the levels of hEGF in patients with gastric cancer were significantly increased. Then, the molecular features of hEGF in the urine of patients with gastric cancer were examined by gel filtration. The elution profile demonstrated that high molecular weight components, which immunologically cross-reacted with hEGF, were considerably increased. On the other hand, the level of normal EGF with a molecular weight of 6500 was decreased to some extent. These results suggest that processing of the EGF precursor into an active EGF molecule is partially suppressed in patients with gastric cancer.
D004815:Epidermal Growth Factor / Q000652:urine*; D005767:Gastrointestinal Diseases / Q000652:urine*; D005770:Gastrointestinal Neoplasms / Q000652:urine*; D006801:Humans; D007106:Immune Sera; D007124:Immunoenzyme Techniques; D012016:Reference Values; D001616:beta-Galactosidase / Q000652:urine
D007106:Immune Sera; D004815:Epidermal Growth Factor; D001616:beta-Galactosidase